Mehta N - Search Results

1

Outcomes after liver transplantation using deceased after circulatory death donors: A comparison of outcomes in the UK and the US.

Ivanics T, Claasen MPAW, Patel MS, Giorgakis E, Khorsandi SE, Srinivasan P, Prachalias A, Menon K, Jassem W, Cortes M, Sayed BA, Mathur AK, Walker K, Taylor R, Heaton N, Mehta N, Segev DL, Massie AB, van der Meulen JHP, Sapisochin G, Wallace D. Ivanics T, et al. Among authors: mehta n. Liver Int. 2023 May;43(5):1107-1119. doi: 10.1111/liv.15537. Epub 2023 Feb 16. Liver Int. 2023. PMID: 36737866

2

Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation.

Mehta N, Yao FY. Mehta N, et al. Liver Transpl. 2013 Oct;19(10):1055-8. doi: 10.1002/lt.23730. Liver Transpl. 2013. PMID: 23959652 Free article. No abstract available.

3

Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.

Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. Mehta N, et al. Liver Transpl. 2013 Dec;19(12):1343-53. doi: 10.1002/lt.23753. Liver Transpl. 2013. PMID: 24285611 Free PMC article.

4

Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list.

Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Mehta N, et al. Liver Transpl. 2014 May;20(5):627-8. doi: 10.1002/lt.23847. Epub 2014 Mar 26. Liver Transpl. 2014. PMID: 24493311 Free PMC article. No abstract available.

5

Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.

Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Hameed B, et al. Among authors: mehta n. Liver Transpl. 2014 Aug;20(8):945-51. doi: 10.1002/lt.23904. Epub 2014 Jul 12. Liver Transpl. 2014. PMID: 24797281 Free PMC article.

6

Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization.

Goel A, Mehta N, Guy J, Fidelman N, Yao F, Roberts J, Terrault N. Goel A, et al. Among authors: mehta n. Liver Transpl. 2014 Oct;20(10):1221-8. doi: 10.1002/lt.23945. Liver Transpl. 2014. PMID: 25045002 Free PMC article.

7

Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.

Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY. Mehta N, et al. JAMA Oncol. 2017 Apr 1;3(4):493-500. doi: 10.1001/jamaoncol.2016.5116. JAMA Oncol. 2017. PMID: 27838698 Free PMC article.

8

Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma.

Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D. Lewin SM, et al. Among authors: mehta n. Liver Transpl. 2017 Aug;23(8):1015-1022. doi: 10.1002/lt.24764. Epub 2017 Jun 26. Liver Transpl. 2017. PMID: 28340509

9

Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma.

Sadler EM, Mehta N, Bhat M, Ghanekar A, Greig PD, Grant DR, Yao F, Sapisochin G. Sadler EM, et al. Among authors: mehta n. Transplantation. 2018 Apr;102(4):640-647. doi: 10.1097/TP.0000000000002043. Transplantation. 2018. PMID: 29319620

10

Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)?

Mehta N, Yao FY. Mehta N, et al. Liver Transpl. 2018 Mar;24(3):327-329. doi: 10.1002/lt.25017. Liver Transpl. 2018. PMID: 29351366 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,741 results

Search Page